SXI Life Sciences
6.905,90
PKT
+48,39
PKT
+0,71
%
Werbung
Analysen zu SXI Life Sciences-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 21.02.05 | Roche Marketperformer | Sparkasse KölnBonn | |
| 09.02.05 | Novartis Buy | Merrill Lynch | |
| 09.02.05 | Roche Buy | Merrill Lynch | |
| 07.02.05 | Roche Buy | Sarasin Research | |
| 07.02.05 | Basilea Pharmaceutica Outperform | Credit Suisse First Boston | |
| 03.02.05 | Roche Buy | Sarasin Research | |
| 03.02.05 | Roche In-Line | Goldman Sachs | |
| 03.02.05 | Roche Kaufen | LB Baden-Württemberg | |
| 03.02.05 | Novartis Übergewichten | Reuschel & Co | |
| 02.02.05 | Roche Buy | Sarasin Research | |
| 02.02.05 | Roche Halten | Helaba Trust | |
| 03.02.05 | Roche Buy | Sarasin Research | |
| 01.02.05 | Novartis Kaufen | SYZ & CO | |
| 01.02.05 | Roche Halten | Helaba Trust | |
| 31.01.05 | Lonza Reduce | Sarasin Research | |
| 31.01.05 | Novartis Outperform | Credit Suisse First Boston | |
| 31.01.05 | Roche Buy | Sarasin Research | |
| 01.02.05 | Roche Neutral | Credit Suisse First Boston | |
| 31.01.05 | Novartis Buy | Helvea | |
| 27.01.05 | Lonza Buy | Helvea | |
| 03.02.05 | Novartis Outperformer | Sparkasse KölnBonn | |
| 26.01.05 | Novartis Market Perform | William Blair | |
| 26.01.05 | Lonza Reduce | Sarasin Research | |
| 25.01.05 | Novartis Halten | LB Baden-Württemberg | |
| 25.01.05 | Lonza Overweight | JP Morgan | |
| 25.01.05 | Novartis Outperform | Goldman Sachs | |
| 25.01.05 | Novartis Buy | Helvea | |
| 24.01.05 | Novartis Overweight | Prudential Securities | |
| 24.01.05 | Novartis Neutral | Sarasin Research | |
| 25.01.05 | Novartis Neutral | Sarasin Research | |
| 24.01.05 | Straumann Outperform | Credit Suisse First Boston | |
| 21.01.05 | Roche Buy | Sarasin Research | |
| 24.01.05 | Lonza Reduce | Sarasin Research | |
| 21.01.05 | Novartis Kaufen | Helaba Trust | |
| 24.01.05 | Novartis Neutral | HypoVereinsbank | |
| 24.01.05 | Novartis Kaufen | Hamburger Sparkasse | |
| 20.01.05 | Novartis Hold | SEB | |
| 20.01.05 | Novartis Akkumulieren | Independent Research | |
| 20.01.05 | Novartis Neutral | Sarasin Research | |
| 21.01.05 | Novartis Buy | Helvea |